

Federica Ricceri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8082910/publications.pdf>

Version: 2024-02-01

33
papers

364
citations

840776

11
h-index

888059

17
g-index

34
all docs

34
docs citations

34
times ranked

620
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single center study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1983-1985.	2.2	4
2	Efficacy and safety of dimethylfumarate in elderly psoriasis patients: a multicentric Italian study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2000-2003.	2.2	7
3	Intellectual Disability and Hidradenitis Suppurativa. <i>Dermatology</i> , 2021, 237, 386-388.	2.1	1
4	Evaluation of expression of Toll-Like Receptors 7 and 9, proliferation, and cytoskeletal biomarkers in plaque and guttate psoriasis: A pilot morphological study. <i>European Journal of Histochemistry</i> , 2021, 65, .	1.5	3
5	Insights into the Pathogenesis of HS and Therapeutical Approaches. <i>Biomedicines</i> , 2021, 9, 1168.	3.2	16
6	Risk of infections in psoriasis: assessment and challenges in daily management. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1211-1220.	3.0	2
7	Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa. <i>Dermatologic Therapy</i> , 2020, 33, e14387.	1.7	13
8	<scp>SB5</scp> adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis. <i>Dermatologic Therapy</i> , 2020, 33, e13435.	1.7	11
9	Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis. <i>Current Pharmaceutical Biotechnology</i> , 2020, 22, 73-84.	1.6	7
10	Elderly psoriatic patients under biological therapies: an Italian experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 143-146.	2.4	29
11	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 273-275.	1.2	39
12	Risk of acute infections in psoriatic patients during biologic therapies is linked to gender. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e362-e364.	2.4	6
13	Clinical experience with the etanercept biosimilar SB4 in psoriatic patients. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 9-12.	2.1	14
14	Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa. <i>Dermatologic Therapy</i> , 2019, 32, e12792.	1.7	11
15	Efficacy and safety of adalimumab after failure of other anti-TNF \pm agents for plaque-type psoriasis: clinician behavior in real life clinical practice. <i>Journal of Dermatological Treatment</i> , 2019, 30, 441-445.	2.2	5
16	Tuscan consensus on the use of UVBnb phototherapy in the treatment of psoriasis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 99-105.	0.8	5
17	Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 305-314.	0.8	19
18	Cutaneous hyperpigmentation induced by apremilast. <i>International Journal of Dermatology</i> , 2018, 57, 473-474.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis. <i>Dermatologic Therapy</i> , 2018, 31, e12614.	1.7	5
20	Lichen planus triggered by <scp>CT</scp> â€P13 and recurrence during secukinumab treatment. <i>British Journal of Dermatology</i> , 2018, 178, 303-304.	1.5	11
21	First case of secukinumab successful therapy in a very elderly psoriatic patient. <i>Dermatologic Therapy</i> , 2018, 31, e12668.	1.7	4
22	Hidradenitis suppurativa and associated diseases. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 8-17.	0.2	14
23	Reply: adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e486.	2.4	2
24	Reduction in psoriasis related pruritus during biologic therapy*. <i>Dermatologic Therapy</i> , 2017, 30, e12442.	1.7	2
25	Clinical characteristics of psoriasis in inflammatory bowel disease patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e414-e416.	2.4	3
26	Epidermal barrier reaction to an in vitro psoriatic microenvironment. <i>Experimental Cell Research</i> , 2017, 360, 180-188.	2.6	11
27	Clinical experience with infliximab biosimilar in psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, e347-e348.	1.5	10
28	A Pediatric Case of Sclerodermatous Graftâ€Versusâ€Host Disease Responsive to Ultraviolet A1 Phototherapy. <i>Pediatric Dermatology</i> , 2016, 33, e99-102.	0.9	4
29	Vitiligo masks malignant acanthosis nigricans in a woman with ovarian cancer. <i>International Journal of Dermatology</i> , 2015, 54, 1300-1302.	1.0	5
30	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , 2015, 14, 864-874.	5.8	25
31	Possible reconsideration of the Nail Psoriasis Severity Index (NAPSI) score. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 1053-1054.	1.2	13
32	Gottron papules: a pathognomonic sign of dermatomyositis. <i>Cmaj</i> , 2013, 185, 148-148.	2.0	5
33	Tumour necrosis factor-Î± antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.5	52